INTRODUCTION
Patients with the disease severe congenital neutropenia (SCN; or Kostmann syndrome) have a bone marrow neutrophil maturation failure that results in neutropenia and life-threatening infections [1] . Maintenance therapy using recombinant human (rh)G-CSF overcomes this maturation arrest and mobilizes the neutrophils into the circulation [2] . The mechanisms causing the pathology of SCN have not been resolved completely, but gene defects in encoding neutrophil elastase 2 (ELA2) or HAX1 confer similar phenotypes [3, 4] . Nonetheless, a number of patients exhibit neither mutation [5] , underscoring the prevailing uncertainty concerning the underlying molecular mechanisms of this disease.
Neutrophils are pivotal in preventing bacterial infections, and most patients with SCN respond to G-CSF with restored blood neutrophil numbers [2] . Despite G-CSF treatment, severe periodontal disease and residual susceptibility to infection often persist [6 -8] , indicating that their neutrophils may be malfunctioning. We have demonstrated previously that the neutrophils from patients with SCN are deficient with respect to expression of the antimicrobial peptide LL-37 and its pro-form pro-LL-37 (human cathelicidin antimicrobial peptide 18 and cathelin-LL-37) [9, 10] , which is normally localized to neutrophil secondary granules, and its processed form, LL-37, is known primarily for its importance as an innate defense molecule with broad and highly efficient antibiotic activity [11] [12] [13] [14] . Additional reported activities of LL-37 include chemoattractant function [15] and inhibition of neutrophil apoptosis [16] . The deficiency of neutrophil pro-LL-37 is a common denominator for patients with SCN, irrespective of genetic mutation or inheritance, and affected individuals may be identified through significantly decreased pro-LL-37 plasma levels [5, 9] .
Neutrophil maturation from myelocytic progenitors occurs in the bone marrow and follows a strictly coordinated program in which the transcription factors C/EBP␣ and PU.1 are critical regulators of early differentiation [17, 18] . Various neutrophil granule proteins are produced at different stages of maturation [19] , and the lineage-specific transcription factor C/EBPε is essential for synthesis of secondary granule proteins [20] . It was demonstrated recently that the hormonal form of vitamin D 3 , [1, 25(OH) 2 D 3 ] , is a strong inducer of pro-LL-37 expression in monocytes/macrophages [21, 22] . A major function of 1,25(OH) 2 D 3 is to control calcium and phosphorus homeostasis and thereby, skeletal development [23, 24] . The observation that a number of patients with SCN present with osteoporosis/ osteopenia [8, 25] and that the gene for LL-37 has vitamin D 3 -responsive elements in the promoter region [21, 22, 26] urged us to investigate whether 1,25(OH) 2 D 3 may play a role in defective pro-LL-37 synthesis.
In this study, we report that the gene encoding pro-LL-37, including the three vitamin-responsive elements, is intact in patients with SCN. However, the pro-LL-37 transcript levels were low in patient neutrophil progenitors, and the major neutrophil differentiation transcription factors were at similar levels to that of healthy subjects. Interestingly, 25(OH)D 3 and 1,25(OH) 2 D 3 could induce pro-LL-37 expression in isolated neutrophil precursors from these patients in vitro, demonstrating that their capacity to produce pro-LL-37 is not hampered.
MATERIALS AND METHODS

Patients and control individuals
Patients with SCN of various inheritances were included ( Table 1) . Patient identity code numbers are consistent with those previously reported [5, 10] . Bone marrow and blood from control subjects included two pediatric, postacute lymphoblastic leukemia (ALL) patients with normal white blood cell counts and bone marrow appearance. Informed consent was obtained from patients, parents, and control individuals. The ethical committees of the Universities of Umeå (Göteborg, Uppsala, Sweden) and Karolinska Institutet (Stolkholm, Sweden) approved this study.
Sequencing of the CAMP gene
DNA was isolated from the lymphocyte fraction of blood using the GeneElute mammalian genomic DNA miniprep kit (Sigma-Aldrich, St. Louis, MO, USA) in accordance with manufacturer's recommendations. The CAMP gene (cathelicidin antimicrobial peptide, available from GenBank/European Molecular Biology Laboratory/DNA DataBank of Japan under Gene ID 820), coding for pro-LL-37 and in addition, 800 bp upstream of the first exon, was sequenced. Phusion DNA polymerase (New England Biolabs, Ipswich, MA, USA), including 1ϫ GC buffer, 0.2 mM each dNTP, and 0.5 M each primer (5Ј-gaa aag atg ggg tca aga agc-3Ј, 5Ј-ctg ggg gtt cca ctg aga atg-3Ј), was used to amplify the gene. The PCR cycle was as follows: 60 s of initial denaturation at 98°C, followed by 35 cycles of 64°C for 30 s, 72°C for 120 s, and 98°C for 15 s. The primers used for sequencing are available upon request.
Neutrophil precursor preparation
Bone marrow (0.5-2 ml) was aspirated with 0.9% sodium chloride with heparin as an anticoagulant, and RBC contamination was reduced through Dextran T500 sedimentation (Amersham Biosciences, Piscataway, NJ, USA). The upper, leukocyte-rich layer was used for enrichment of myeloid precursors by density centrifugation using a two-layer discontinuous Percoll (Amersham Biosciences) gradient as described previously [27, 28] . The more mature cells (mainly myelocytes and metamyelocytes) floating above the pellet and the early progenitor cells (mainly myeloblasts and promyelocytes) present in the interface between the different Percoll layers were pooled, representing a neutrophil precursor cell fraction. The pellet, which mainly contains band cells and mature neutrophils, was not used in these experiments.
Isolation of neutrophil precursors by flow cytometry
The neutrophil precursor cells derived from 10 patients and two control individuals were resuspended in ice-cold buffer (PBS with 1% BSA and 0.1% sodium azide) and labeled with FITC-conjugated mouse anti-human CD13 and retinal pigment epithelium-conjugated monoclonal mouse anti-human CD11b (Dako A/S, Glostrup, Denmark). Alternatively, dextran-sedimented bone marrow cells from two patients were labeled as above but without prior Percoll density centrifugation. Cells were gated for by granularity and size (P1) and subsequently sorted into CD11b low and CD11b high differentiation stage populations using a FACScan Vantage SE sorter (Becton Dickinson, Franklin Lakes, NJ, USA). The expression of CD11b and CD13 antigens varies with neutrophil precursor maturation [29 -31] 
RNA isolation, RT-PCR, and transcript analysis
Total RNA was prepared from 0.3-1 ϫ 10 6 flow cytometer-sorted cell populations using the SV Total RNA isolation system (Promega, Madison, WI, USA) or alternatively, the RNeasy min kit (Qiagen, Hilden, Germany). The synthesis of first-strand cDNA was accomplished using the ImProm-II™ RT system (Promega), both steps in accordance with the manufacturer's instructions.
Power SYBR Green PCR master mix and ABI 7900FAST machine (both from Applied Biosystems, Foster City, CA, USA) were used to determine pro-LL-37 (5Ј-aacctctaccgcctcctggacctg-3Ј, 5Ј-caatcctctggtgactgctgtgtcg-3Ј), C/EBP␣ (5Ј-accttgtgccttggaaatgc-3Ј, 5Ј-ggggtctgctgtagcctcg-3Ј), and GAPDH (5Ј-tgccatcactgccacccagaag-3Ј, 5Ј-atgaccttgcccacagccttgg-3Ј) transcript levels. The quantitative PCR (qPCR) cycle was as follows: 50°C for 2 min and 95°C for 10 min of initial denaturation, followed by 35 cycles of 95°C for 15 s and 60°C for 30 s. TaqMan fast universal PCR master mix was used to determine C/EBPε (hs00357657m1), PU.1 (hs02786711m1), and GAPDH (Hs99999905m1) transcript levels (all from Applied Biosystems) using standard conditions from the manufacturer. Target gene mRNA expression levels were assessed with the ⌬ comparative threshold method for comparative quantification and given as percent of GAPDH. Transcripts of human neutrophil peptide 1-3 (HNP1-3) were assessed using PCR Core System II (Promega) with sequence-specific primers as described in ref. [32] but with 35 cycles and double-repetitive annealing, extension, and denaturing BMT, Bone marrow transplantation at 7 months of age resulted in chimerism; wt, wild-type.
times. ␤-Actin was amplified as in ref. [33] , except for running 31 cycles. The reaction products were analyzed using 1% agarose gel. Band intensity was determined with Image J for HNP1-3 and ␤-actin (NIH Image program, http://rsb.info.nih.gov/nih-image), given as percent of ␤-actin.
Stimulation of EBV-transformed B cells
EBV-transformed B lymphoblastoid cell lines from one patient with SCN as well as from one healthy sibling were a generous gift from Hans G. Boman and Ingemar Ernberg (Karolinska Institutet). Transformed cells were stimulated at a density of 0.8 ϫ 10 9 cells/L in RPMI including 15 mM Hepes for 3-4 days at 37°C supplemented with 100 nM 1,25(OH) 2 D 3 or different concentrations of all-trans retinoic acid (ATRA; both from Sigma-Aldrich). Cell culture medium and cells were harvested by centrifugation (200 g). The cell culture medium was concentrated using Sep-Pak light tC18 cartridges (Waters), according to the manufacturer's recommendation with 0.1% trifluoroacetic acid (TFA) in water as conditioner and wash solvent. The cartridges were washed further with 0.1% TFA in 30% acetonitrile, and bound proteins were eluted with 0.1% TFA in 60% acetonitrile. The eluted proteins were frozen, lyophilized, and resuspended in NuPAGE lithium dodecyl sulfate (LDS) sample buffer (Invitrogen, Carlsbad, CA, USA), thus obtaining a 50ϫ concentrate of the original cell culture medium. Equal numbers of seeded cells from each well were snapfrozen and stored at -80°C until use.
Neutrophil precursor stimulation
Neutrophil precursor cells were seeded at a density of 0.8 -1 ϫ 10 9 cells/L and maintained in Stem-Pro-34 SFM basal liquid medium (Invitrogen) or in RPMI medium with 15 mM Hepes. The medium was supplemented with 2% autologous bone marrow plasma and 5 ng/ml rhG-CSF (Sigma-Aldrich). Cells were stimulated for 12 h-5 days at 37°C with 12-120 nM 1,25(OH) 2 D 3 , 1 M ATRA, 100 nM 25(OH)D 3 , 1 M cholecalciferol, or 1 M 9-cis retinoic acid. The cell culture medium from each experiment was collected following centrifugation (200 g). Equal numbers of seeded cells from each well were snap-frozen and stored at -80°C until resuspension in immunoblot sample buffer, or alternatively, RNA was isolated using the RNeasy min kit (Qiagen).
SDS-PAGE and immunoblotting
Samples for immunoblots were dissolved in NuPAGE LDS sample buffer (Invitrogen) including 10% ␤-ME and heated at 70°C before loading. Proteins were separated in 1.0 mm 4 -12% NuPAGE Bis-Tris gel (Invitrogen), and immunoblotting was performed as described [10] using the following antibodies: goat anti-rabbit IgG (H ϩ L; BioRad Laboratories, Hercules, CA, USA), rabbit anti-LL-37 (Innovagen, Lund, Sweden [9] ), and rabbit anti-actin (directed against residues 20 -33; Sigma-Aldrich). The pro-LL-37 signal from the cell culture medium was normalized to the number of cells in each well, and equal numbers of seeded cells from each well were dissolved in loading buffer.
RESULTS
Patients with SCN display low pro-LL-37 transcript levels in neutrophil precursors
We analyzed pro-LL-37 and the ␣-defensins HNP1-3 transcript levels in bone marrow neutrophil progenitors representing early and late stages of maturation. One typical example of the CD13/CD11b expression profile of cells at different maturation stages during normal neutrophil maturation is displayed in Figure 1B and a representative plot from one patient with SCN in Figure 1C . In patients with SCN, the G-CSF-driven myeloid maturation generated a higher proportion of the more mature BS cell population, although the earlier myeloid maturation stages were represented but at lower numbers compared with the control (Fig. 1C, and data not included) .
Pro-LL-37 synthesis commences at the myelocyte-to-metamyelocyte stage of neutrophil maturation in the bone marrow, and HNP1-3 synthesis begins earlier at the myeloblast-to-promyelocyte stage [19, 34] . From Figure 1D , it is clear that pro-LL-37 transcripts were deficient in the neutrophil progenitors of all patients tested, irrespective of the presence or absence or type of disease-associated mutations (Table 1) , and the control individuals, as expected, exhibited high levels of the transcript in the neutrophil precursors of late-maturation stage (CD11b high ). Conversely, the transcript levels for HNP1-3 did not differ between patients and control and were readily detectable in early-and late-stage populations (Fig. 1E) . The patients' deficiency of pro-LL-37 transcripts is not likely to be caused by the G-CSF therapy, as stem-cell donors receiving G-CSF displayed neutrophil pro-LL-37 protein levels almost as high as prior to G-CSF treatment (data not included). The slight reduction may be a result of increased release from neutrophil granules or a function of G-CSF-accelerated bone marrow transit.
Deficiency of pro-LL-37 transcripts is neither a result of mutations in the gene coding for pro-LL-37 (CAMP) nor lack of key transcription factors for neutrophil differentiation
We next analyzed the CAMP gene for mutations by sequencing the entire gene as well as 800 bp of the 5Ј-UTR region that contains binding sites for vitamin D-response elements, PU.1, C/EBPs, and other potential transcription factors [22] (Fig. 1I) . Neither mutations in the CAMP gene nor the upstream region were detected in the four patients analyzed. These patients harbor one of two different ELA2 mutations or one HAX1 mutation or display no known disease-associated mutation, respectively (Table 1) .
Major transcription factors governing neutrophil differentiation include C/EBP␣, C/EBPε, and PU.1. Their transcripts were measured by qRT-PCR (Fig. 1, F-H ) in early (CD11b low ) and late (CD11b high ) differentiation stage populations. Overall, the transcript levels of C/EBP␣, C/EBPε, and PU.1 displayed no major difference between controls and SCN individuals. For C/EBPε, a slight reduction in patient neutrophils at the early stage of maturation was noted, but the difference, less than twofold, was not conclusive in view of the variation in patient sample range (Fig. 1G) .
Lymphoblastoid cells from patients with SCN produce pro-LL-37 in response to vitamin D 3
Lymphocytes are known to produce low levels of endogenous pro-LL-37, and its production can be elevated by different inducers [32] . We therefore investigated whether EBV-transformed B cells from a patient with SCN had the capacity to produce pro-LL-37. Cells from a patient and a sibling produced pro-LL-37 following stimulation with the 1,25(OH) 2 D 3 ( Fig. 2A) . This induction was time-and concentration-dependent using physiological concentrations of 1,25(OH) 2 D 3 ranging from 0.01 to 10 nM (data not included). We also investigated the effect of ATRA, and Figure 2B illustrates that EBV-transformed B cells produce pro-LL-37 in a concentration-dependent manner similar to that induced by 1,25(OH) 2 D 3 . The stimulation was time-dependent, with increased protein concentrations in the cell culture medium following 3 days of stimulation (data not included). These experiments demonstrate that cells of the lymphoid lineage from a patient with SCN have the ability to transcribe and translate pro-LL-37.
Neutrophil precursors from patients with SCN have the capacity to produce pro-LL-37 protein in vitro
We next evaluated the responsiveness of patient myeloid cells to 1,25(OH) 2 D 3 , ATRA, or a combination of these, respectively. A pronounced induction of pro-LL-37 was noted when neutrophil precursors from patients as well as from control qindividuals were incubated with 1,25(OH) 2 D 3 (Fig. 3, A and B) . The induction was time-dependent, and at 3.5 days, pro-LL-37 was detected in collected cells as well as in the cell culture medium (Fig. 3B) , whereas after 5 days, pro-LL-37 was mainly noticeable in the culture medium (Fig. 3A) . In contrast to the bone marrow cells, blood-derived, mature neutrophils from controls and patients did not respond with pro-LL-37 production following 1,25(OH) 2 D 3 stimulation (data not included).
Unlike for the transformed B cells, neither ATRA nor the geometric isomer of ATRA, 9-cis retinoic acid, induced pro-LL-37 synthesis in neutrophil precursors (Fig. 3, A-C) . ATRA and 1,25(OH) 2 D 3 , in combination, counteracted the pro-LL-37 synthesis obtained with vitamin D 3 alone (Fig. 3, A and B) , and the reduction of pro-LL-37 was evident in cells and supernatants ( Table 2 . Both molecules were within reference values, suggesting that the patients have no major defect in vitamin D 3 metabolism.
One patient was administered a low dose of 1,25(OH) 2 D 3 daily in an effort to prevent osteopenia (Table 1) . Plasma levels of pro-LL-37 were measured before, during, and after therapy, but no induction of pro-LL-37 protein was observed (data not included). (Fig. 3C) , indicating that the vitamin D 3 -converting enzymes of the patients are functional.
1,25(OH) 2 D 3 -Induced pro-LL-37 transcription does not correlate with increased C/EBP transcription
C/EBPε is a major transcription factor for the genes encoding the secondary granule proteins during neutrophil maturation in the bone marrow [20] . Pro-LL-37 and C/EBPε transcripts were therefore monitored following 1,25(OH) 2 D 3 and ATRA stimulation (Fig. 4, A and B) . No concomitant induction of C/EBPε could be noted, indicating that C/EBPε is not involved in Table 1 ). Table 1 ). n.d., Not determined.
1,25(OH) 2 D 3 -induced pro-LL-37 synthesis. Figure 4A also demonstrates that pro-LL-37 transcripts are generated following combined ATRA/1,25(OH) 2 D 3 stimulation, suggesting that the vitamin D 3 -induced transcription of the pro-LL-37 gene is subject to further regulation post-transcriptionally, as the combination reduced pro-LL-37 at a protein level (Fig. 3, A and B) .
DISCUSSION
We have reported recently that the antimicrobial propeptide pro-LL-37 is deficient in neutrophils of patients with SCN, which is contrary to patients with autoimmune and idiopathic neutropenia and may therefore serve as a phenotypic biomarker for SCN [5, 9] . In the current study, we indicate that the defect in pro-LL-37 protein synthesis most likely arises as a function of inadequate transcription. This conclusion is based on the findings that isolated neutrophil precursor cells from patients with SCN displayed low levels of pro-LL-37 mRNA, and there were no mutation(s) in the gene coding for pro-LL-37 (CAMP) or in the CAMP promoter region. The 1,25(OH) 2 D 3 and its precursor forms, however, increased the synthesis of pro-LL-37 in neutrophil precursor cells in vitro, demonstrating that the bone marrow neutrophil precursors indeed have the capacity to produce pro-LL-37.
The differentiation of cells within the myeloid lineage is influenced by extracellular signals provided by cytokines and the nuclear receptor ligands 1,25(OH) 2 D 3 and ATRA [36] . There are three putative vitamin D 3 -and vitamin A-responsive elements in the promoter of CAMP (Fig. 1I ) of the DR3 and DR5 type [26] , indicating that ATRA and 1,25(OH) 2 D 3 are potential regulators of the gene. ATRA and 1,25(OH) 2 D 3 were herein used to evaluate the inducibility of the CAMP gene in cells from patients with SCN. ATRA did not induce any pro-LL-37 production in bone marrow-derived neutrophil precursors but did so in patient-derived, EBV-transformed B cells, thus demonstrating that lymphocytes from patients with SCN have the capacity to produce pro-LL-37. The unresponsiveness of patient myeloid cells to ATRA concords with the unchanged pro-LL-37 expression following ATRA stimulation in bone marrow mononuclear cells and the myeloid cell lines NB4 and HL-60, reported by An et al. [37] . In contrast to ATRA, 1,25(OH) 2 D 3 stimulation of neutrophil precursors from three SCN patients (with ELA2, HAX1, or no known disease-associated mutation, respectively) all responded by pro-LL-37 production, as did the EBV-transformed B cells. These results further underscore the intricate regulation of pro-LL-37 in cells of different lineages [38] .
We have no indication that the pro-LL-37 dysregulation is a result of aberrant vitamin D 3 metabolism, as the systemic levels of 1,25(OH) 2 Table 1 ) may have been a result of use of too low of a dose rather than malfunctioning vitamin D 3 metabolism. We cannot exclude, however, that the proportion of minor, more polar metabolites of 25(OH)D 3 exhibiting lower biological activity compared with 1,25(OH) 2 D 3 is different in patients compared with in healthy individuals [39] .
The basal levels of the instrumental transcription factors C/EBP␣ and PU.1, which govern early myeloid differentiation in patient bone marrow precursors, did not differ from that of healthy individuals. Gene-inactivating mutations in the neutrophil lineage-specific transcription factor C/EBPε have been identified in patients with specific granule deficiency [20] , a rare neutrophil disorder, but unlike those patients [40] , the neutrophils derived from patients with SCN contained lactoferrin and gelatinase [10] . A major defect in C/EBPε-driven transcription is therefore unlikely. In addition, the level of C/EBPε transcripts in neutrophil progenitors was similar to that of controls. Mutations in the transcription regulator growth factor-independent 1 (Gfi1) have been recorded in a few patients with SCN [41] , and transfer of one gene-inactivating mutation to a mouse model rendered the mouse neutropenic [42] . PU.1 and C/EBPε are negatively regulated by GFI1 during myelopoiesis [43] . However, the transcript levels of PU.1 and C/EBPε were similar to control individuals in the present group of patients with SCN, suggesting that GFI1 is functional. It is therefore unlikely that GFI1 is involved in the pro-LL-37 deficiency.
The CAMP gene is transcribed during neutrophil differentiation in the bone marrow, commencing at the myelocyte stage of maturation [44] . ATRA and 1,25(OH) 2 D 3 have opposing effects on early myeloid precursors in such a way that 1,25(OH) 2 D 3 preferentially directs myeloid precursors to the monocytic lineage, and ATRA guides them toward the neutrophil lineage [45] . The early neutrophil precursors, the promyelocytes, may redirect toward monocytes/macrophages in vitro in response to 1,25(OH) 2 D 3, regardless of the presence of G-CSF [46] . It may be argued that the pro-LL-37-inducing effect of 1,25(OH) 2 D 3 reflects production from cells differentiating toward the monocytic lineage. The reported level of pro-LL-37 produced by monocytes is, however, low, and therefore, the high levels in patient progenitors most likely derive from cells of the neutrophil lineage [47] . When a combination of 1,25(OH) 2 D 3 and ATRA was used for stimulation, pro-LL-37 protein levels were reduced. The induction at the mRNA level, however, was not compromised by coincubation with ATRA, suggesting that pro-LL-37 may, in addition, be posttrancriptionally regulated. Interestingly, 1,25(OH) 2 D 3 -induced pro-LL-37 transcription correlated inversely with C/EBPε transcription levels, suggesting that transcription factor(s) other than C/EBPε are active in 1,25(OH) 2 D 3 -induced pro-LL-37 synthesis.
In summary, myeloid precursors of patients with SCN responded to 1,25(OH) 2 D 3 with pro-LL-37 transcription and protein synthesis. We could not detect any alterations in the vitamin D 3 synthesis pathways that could explain the prevailing neutrophil pro-LL-37 deficiency. We conclude that the deficiency is most likely a result of improper transcriptional regulation during myelopoiesis, as the pro-LL-37 gene was functionally accessible by 1,25(OH) 2 D 3 in EBV-transformed B cells as well as in neutrophil precursor cells in vitro. Neutrophil differentiation can be induced through more than one pathway, as demonstrated by others [48] . It may be that the forced myelopoiesis induced by pharmacological doses of G-CSF fails to recruit transcription factors essential for pro-LL-37 synthesis or alternatively, that there is an inherent defect in specific transcription regulator(s) necessary for pro-LL-37 production. Further identification of components involved in the defective transcription of the CAMP gene may provide tools for elevating pro-LL-37 levels, which in turn, may therapeutically benefit patients with SCN.
ACKNOWLEDGMENTS
This work was supported by the Swedish Research Council (06X-12634 to M. A. and 06XD-14653 to K. P.), the Swedish Society for Medical Research (to K. P.), the King Oscar II Jubilee Foundation (to M. A.), the Magnus Bergwall Foundation (to M. A.), the Swedish Medical Society (to K. P.), the Åke Wiberg foundation (to K. P.), the Swedish Children's Cancer Foundation (to G. C.), and the Söderbergska stiftelsen. We are grateful to all patients and their families and physicians. We acknowledge Hans G. Boman and Ingemar Ernberg for their generous gift of cell lines and for valuable discussions. We are grateful to Anita Vestman for cell culture assistance, Birgitta Wester for FACS analyses, and Robert A. Harris for linguistic advice. We also acknowledge Charles L. Bevins and Wilhelm Paulander for PCR assistance and Ramona Petersson for immunoblot analyses.
